The therapeutic potential of targeting glucagon-like peptide-1 (GLP-1) has become increasingly evident over the past 20 years, both as notable diabetes and weight loss drugs, such as exenatide, liraglutide, and semiglutide, and as drug candidates beyond insulin regulation. Research in this field has progressed from a niche focus on diabetes to a powerful therapeutic platform with far-reaching implications for human health.
Looking beyond GLP-1 as a singular drug target and considering its multifaceted roles in metabolism may help scientists uncover treatment opportunities in cardiovascular and neurological diseases. In this Innovation Spotlight, Dale Wright, executive director of inflammation & systems biology and Brian Bond, vice president of drug discovery and translational sciences at Inotiv, discuss the importance of taking a holistic approach to GLP-1 therapeutic research using systems pharmacology.
Connect With Our Scientific Team
Have questions or want to discuss a study?
